King & Spalding announce appointment of former FDA official

pharmafile | April 27, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Eva Temkin, a former senior FDA official for therapeutic biologics and biosimilars, has joined King & Spalding in Washington, US, as a partner on the FDA and Life Sciences team.

At the FDA, Temkin served as Acting Director for Policy at the Office of Therapeutic Biologics and Biosimilars from 2019 to 2021. She joined the agency in 2013 and held a variety of roles, including senior regulatory counsel at the Office of Therapeutic Biologics and Biosimilars.

Mark Brown, Chair of King & Spalding’s FDA and Life Sciences team commented: “Eva is uniquely qualified to help clients navigate the complex landscape of the dynamic and evolving therapeutic biologics industry, which is often not well-understood by industry, investors, and other interested parties.”

Related Content

No items found

Latest content